TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease

Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.

SEATTLE, WASHINGTON, October 22, 2014 — TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company’s PolyStart technology is on TapImmune’s cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.

The use of the Company’s PolyStart technology increases the production of proprietary antigenic peptides of the vaccine by as much as FOUR-fold, thereby increasing vaccine potency (presenting more antigen), and potentially making manufacturing and commercialization of large volume vaccines more cost effective. While additional preclinical development is in progress, we fundamentally believe that our technology will have a significant impact in the development of vaccines for both cancer and emerging viral-disease (e.g., Ebola, Enterovirus etc).

Successful proof-of-concept studies conducted in collaboration with Mayo Clinic clearly demonstrated that human cells containing a PolyStart construct containing vaccinia virus (“smallpox”) antigens (antigenic peptides) could naturally express, process and present these antigens on the cell surface and that cell surface presentation occurred in a manner recognizable by immune system cells (e.g., CD8+ killer T-cells). Importantly, CD8+ T-cells recognizing a PolyStart-encoded antigenic peptide on the cell surface will destroy that cell. In addition, T-cells recognizing the antigenic peptide are stimulated to expand in number, thereby providing a strong longer-lived capacity to destroy many more cells infected with the virus.

TapImmune is actively seeking partnerships and collaborations for development of PolyStart for the treatment of emerging viral threats.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACTS:

Glynn Wilson, PH.D.

Chairman & CEO

(866)-359-7541

Investor Relations

J.Streicher Capital, LLC.

Robert Giordano

Tel: 212-257-5495

Cell: 917-327-3938

Email: rgiordano@jstreichercapital.com